Two drinks now land like five, and I found that out in a way I would rather not repeat.
What I actually want to know is whether the change in tolerance is the smaller stomach, the smaller body, or something central, and whether it settles.
I have searched first, so if this is covered somewhere point me at it and I will read it.
Answering the narrow version, because the broad one does not have a single answer. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
I would rather be corrected than agreed with, if it comes to it.
Dr.NateNeph said:The liver data is among the strongest non-weight findings in the class.
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsSallyK_inj said:Two drinks now land like five, and I found that out in a way I would rather not repeat.
This matches mine closely enough to be worth saying so out loud.
From the other side of the consultation, briefly. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.